Here's your drug review and approval news in brief: holiday season of mass approvals has continued on, highlighted by the US FDA's backing of Novo Nordisk AS' Ozempic (semaglutide) for the treatment of type 2 diabates. The approval was No. 41 in the agency's 2017 new drug approval count.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?